Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell INSM and other ETFs, options, and stocks.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,271
Employees1,271
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,271
Employees1,271

INSM Key Statistics

Market cap
33.62B
Market cap33.62B
Price-Earnings ratio
-27.56
Price-Earnings ratio-27.56
Dividend yield
Dividend yield
Average volume
2.25M
Average volume2.25M
High today
$160.62
High today$160.62
Low today
$157.54
Low today$157.54
Open price
$157.76
Open price$157.76
Volume
381.71K
Volume381.71K
52 Week high
$160.62
52 Week high$160.62
52 Week low
$60.40
52 Week low$60.40

INSM News

Simply Wall St 3d
A Fresh Look at Insmed Valuation Following Its Recent Momentum

Insmed (INSM) has delivered a strong performance in recent weeks, catching the attention of investors who track momentum in biotech stocks. Shares have climbed...

A Fresh Look at Insmed Valuation Following Its Recent Momentum
Simply Wall St 3d
Analyzing Insmed Stock After Positive FDA Filing News and Triple Digit Gains in 2025

If you’re wondering what to make of Insmed after its recent run, you’re not alone. It seems like every time you check the stock, it’s making new headlines. With...

Analyzing Insmed Stock After Positive FDA Filing News and Triple Digit Gains in 2025
TipRanks 4d
Insmed price target raised to $193 from $154 at TD Cowen

TD Cowen raised the firm’s price target on Insmed (INSM) to $193 from $154 and keeps a Buy rating on the shares. The firm noted the company presented its impres...

Analyst ratings

95%

of 20 ratings
Buy
95%
Hold
5%
Sell
0%

More INSM News

TipRanks 5d
Insmed’s TPIP Shows Promising Phase 2 Results, Boosting Buy Rating and Future Prospects

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Insmed, with a price target of $193.00. Elevate Your Investing Strategy: Take ad...

TipRanks 5d
Insmed price target raised to $180 from $110 at Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Insmed (INSM) to $180 from $110 and keeps an Outperform rating on the shares. The fir...

Nasdaq 6d
INSM Quantitative Stock Analysis

Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our P/B Growth Investor model ba...

INSM Quantitative Stock Analysis
TipRanks 6d
Measured Optimism and Caution: Maxwell Skor’s Hold Rating on Insmed Amid Promising Brinsupri Launch

Analyst Maxwell Skor of Morgan Stanley maintained a Hold rating on Insmed, retaining the price target of $144.00. Elevate Your Investing Strategy: Take advantag...

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.